BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
Real-time Estimate Cboe BZX  -  09:02 2022-08-16 am EDT
74.54 USD   +0.01%
07:59aBristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
MT
07:00aBristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
BU
08/10Gentibio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
74.96(c) 74.86(c) 74.46(c) 75.57(c) 74.53(c) Last
8 978 661 8 319 071 6 142 959 6 163 935 11 125 560 Volume
+1.57% -0.13% -0.53% +1.49% -1.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 46 180 M - -
Net income 2022 6 621 M - -
Net Debt 2022 24 639 M - -
P/E ratio 2022 26,8x
Yield 2022 2,85%
Sales 2023 47 868 M - -
Net income 2023 8 791 M - -
Net Debt 2023 15 408 M - -
P/E ratio 2023 15,2x
Yield 2023 2,99%
Capitalization 159 B 159 B -
EV / Sales 2022 3,98x
EV / Sales 2023 3,65x
Nbr of Employees 32 200
Free-Float 73,0%
More Financials
Company
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. La répartition géographique du CA est la suivante : Etats-Unis (63%), Europe (23%) et autres (14%). 
Sector
Pharmaceuticals
Calendar
10/26 | 06:59amEarnings Release
More about the company
Ratings of Bristol-Myers Squibb Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
07:59aBristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Dea..
MT
07:00aBristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Wait..
BU
08/10Gentibio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg T..
CI
08/10Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Show..
BU
08/10Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3
CI
08/10Bristol Myers, 2seventy Earlier-Use Abecma Study Meets Main Endpoint
DJ
08/03Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 Highlights
BU
07/29WALL STREET STOCK EXCHANGE : Bad news is good news
MS
07/29Bristol-Myers Says Trial of Drug Combination to Treat Kidney Cancer Failed to Meet Prim..
MT
07/29Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolum..
BU
07/29Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo Plus Yer..
CI
07/29BRISTOL MYERS SQUIBB : Opdivo Plus Yervoy Didn't Meet Primary Endpoint in Cancer Study
DJ
07/28UBS Adjusts Bristol-Myers Squibb Company Price Target to $75 From $73, Maintains Neutra..
MT
07/28Morgan Stanley Cuts Bristol-Myers Squibb Company's Price Target to $61 From $63, Keeps ..
MT
07/28JPMorgan Raises Price Target for Bristol-Myers Squibb Company to $85 From $80, Maintain..
MT
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
08/10Gentibio annonce une collaboration avec Bristol Myers Squibb pour développer des thérap..
08/10Bristol Myers Squibb et 2seventy bio, Inc. annoncent les premiers résultats de KarMMa-3
07/29Bristol-Myers déclare que l'essai d'une combinaison de médicaments pour traiter le canc..
07/29Bristol Myers Squibb fait le point sur l'essai CheckMate -914 évaluant Opdivo (nivoluma..
07/28UN ACHETEUR INCONNU A ACQUIS LES OPÉ : Bmy).
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 74,53 $
Average target price 80,36 $
Spread / Average Target 7,83%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Samit Hirawat Chief Medical Officer-Global Drug Development
Rupert J. Vessey Executive VP-Research & Early Development
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY19.53%159 141
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582